NCT06034535

CD62L Depleted Donor Lymphocyte Infusion With T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (estimated)
• Sponsor: Hong Kong Children's Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this clinical trial, the investigators aim to apply CD62L depleted donor lymphocyte infusion (DLI) together with in vitro T cell depleted haploidentical hematopoietic stem cell transplantation (HSCT) to treat patients with malignant or non-malignant disease in need of HSCT. The investigators shall evaluate the graft failure-free, graft-versus-host disease (GVHD)-free survival at one year, frequency of adverse events and post-transplant complications, and immunoreconstitution.

Detailed description

The peripheral stem cell harvest product from the patient's related haploidential donor will be divided into two portions. One portion will undergo T cell receptor (TCR) αβ depletion and the other portion will undergo CD62L depletion. Both depleted products will be infused intravenously to the patient on the same day.

Conditions

• Hematopoietic Organs; Disorder

Interventions

Type	Name	Description
BIOLOGICAL	CD62L depleted donor lymphocyte infusion	Intravenous infusion of CD62L depleted donor lymphocytes

Timeline

• Start date: 2023-09-01
• Primary completion: 2025-09-01
• Completion: 2026-09-01
• First posted: 2023-09-13
• Last updated: 2025-09-15

Locations

1 site across 1 country: Hong Kong